News

According to the company, the job reductions are aimed at trimming down its 6,500-person US sales force. However, the company did not disclose the number of job cuts.

If approved, Yondelis combined with Doxil and Caelyx will provide a new, non-platinum treatment option for these patients in Europe. The application follows the completion of a multicenter,

Mr Curtin will also be responsible for Octapharma’s recovered plasma program operated in conjunction with Group Services for America’s Blood Centers and Octapharma’s source plasma contracts with independent

The patents form the basis for the development of diagnostic tests in cardiovascular disease, diabetes, degenerative diseases of aging, cancer and other diseases, by measuring increased oxidative damage

The company’s Germantown facility will continue to house certain personnel and functions, including MiddleBrook’s R&D group. The newly leased 14,971sqft Westlake facility is expected to house up to

Previously, Perrigo was sued for patent infringement of US patents based upon its filing of an abbreviated new drug application containing a Paragraph IV certification. Under the terms

Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a new drug application. Loretta Itri,

According to the company, the new nasal drop includes active ingredients found in traditional Chinese medicines with minimum side effects. There are currently five enterprises who have received

Since September 2007, Dr Parkinson has served as president and CEO of Nodality, a South San Francisco, California-based biotechnology company. Dr Parkinson has received his MD degree from